SG11201906728TA - Multimeric oligonucleotides having decreased kidney clearance - Google Patents
Multimeric oligonucleotides having decreased kidney clearanceInfo
- Publication number
- SG11201906728TA SG11201906728TA SG11201906728TA SG11201906728TA SG11201906728TA SG 11201906728T A SG11201906728T A SG 11201906728TA SG 11201906728T A SG11201906728T A SG 11201906728TA SG 11201906728T A SG11201906728T A SG 11201906728TA SG 11201906728T A SG11201906728T A SG 11201906728TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- multimeric oligonucleotides
- pct
- oligonucleotides
- multimeric
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title abstract 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 6
- 230000003247 decreasing effect Effects 0.000 title abstract 2
- 210000003734 kidney Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 230000024924 glomerular filtration Effects 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Plant Pathology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
HONH HO HO NH (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) W I PO I PCT o °nolo olommoollmoiliflo oimIE (10) International Publication Number WO 2018/145086 Al (51) International Patent Classification: A61K 31/7105 (2006.01) A61K 48/00 (2006.01) A61K 31/712 (2006.01) C07H 21/02 (2006.01) A61K 31/713 (2006.01) C07H 21/04 (2006.01) (21) International Application Number: PCT/US2018/017062 (22) International Filing Date: 06 February 2018 (06.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/455,231 06 February 2017 (06.02.2017) US 62/522,363 20 June 2017 (20.06.2017) US 62/561,853 22 September 2017 (22.09.2017) US (71) Applicant: MPEG LA, LLC [US/US]; 5425 Wisconsin Avenue, Suite 801, Chevy Chase, MD 20815 (US). (72) Inventors: NEUMAN, Kristin, K.H.; 10 Sackett Drive, Larchmont, NY 10538 (US). BROWN, Jonathan, Miles; Mpeg LA, LLC, 5425 Wisconsin Avenue, Suite 801, Chevy Chase, MD 20815 (US). VORNLOCHER, Hans-peter; Axolabs GmbH, Fritz-hornschuch-strar3e 9, D-95326 Kulm- bach (DE). (74) Agent: LINNIK, Konstantin et al.; Nutter McClennen & Fish LLP, Seaport West, 155 Seaport Boulevard, Boston, MA 02210-2604 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, = (54) Title: MULTIMERIC OLIGONUCLEOTIDES HAVING DECREASED KIDNEY CLEARANCE W O 20 18/ 145 086 Al HO HO HO - NH O\ HO HO HO - NH O d \ FIG. 1A (57) : The present invention relates to methods of administering to a subject multimeric oligonucleotides having monomeric subunits joined by linkers. The multimeric oligonucleotides have a molecular weight of at least about 45 kD and other characteristics, such that their clearance due to glomerular filtration is reduced. The present invention also relates to such multimeric oligonucleotides and methods of synthesizing such multimeric oligonucleotides. [Continued on next page] WO 2018/145086 Al MIDEDIMOMMIDIREI013010HEINIIMEIMMOIMIE EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762455231P | 2017-02-06 | 2017-02-06 | |
US201762522363P | 2017-06-20 | 2017-06-20 | |
US201762561853P | 2017-09-22 | 2017-09-22 | |
PCT/US2018/017062 WO2018145086A1 (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201906728TA true SG11201906728TA (en) | 2019-08-27 |
Family
ID=63039118
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201906728TA SG11201906728TA (en) | 2017-02-06 | 2018-02-06 | Multimeric oligonucleotides having decreased kidney clearance |
Country Status (11)
Country | Link |
---|---|
US (2) | US11078484B2 (en) |
EP (1) | EP3576752A4 (en) |
JP (1) | JP7183167B2 (en) |
KR (2) | KR102623311B1 (en) |
CN (1) | CN110248665A (en) |
AU (1) | AU2018215684B2 (en) |
CA (1) | CA3051480A1 (en) |
IL (2) | IL267806B2 (en) |
MX (1) | MX2019009347A (en) |
SG (1) | SG11201906728TA (en) |
WO (1) | WO2018145086A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101141544B1 (en) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | Multi-conjugate of siRNA and preparing method thereof |
CN108026527B (en) | 2015-06-15 | 2022-05-10 | Mpeg La有限责任公司 | Defined multiconjugated oligonucleotides |
US20230287406A1 (en) * | 2019-03-04 | 2023-09-14 | Mpeg La, L.L.C. | Multimeric oligonucleotides with enhanced bioactivity |
US20200385737A1 (en) * | 2019-03-29 | 2020-12-10 | University Of Massachusetts | OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72 |
EP3966328A4 (en) | 2019-05-06 | 2023-10-18 | University Of Massachusetts | Anti-c9orf72 oligonucleotides and related methods |
JP2022543191A (en) * | 2019-07-30 | 2022-10-11 | エムペグ エルエイ リミテッド ライアビリティ カンパニー | Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity |
WO2021026476A1 (en) * | 2019-08-08 | 2021-02-11 | Mpeg La, L.L.C. | Complement targeting with multimeric oligonucleotides |
WO2021222635A2 (en) * | 2020-04-30 | 2021-11-04 | Mpeg La, L.L.C. | Multimeric oligonucleotides with divided strands |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9207381D0 (en) | 1992-04-03 | 1992-05-13 | Ici Plc | Synthesis of oligonucleotides |
AU2003282722A1 (en) | 2002-10-02 | 2004-04-23 | Alnylam Pharmaceuticals Inc. | Therapeutic compositions |
EP3450559A1 (en) | 2003-03-07 | 2019-03-06 | Alnylam Pharmaceuticals, Inc. | Therapeutic compositions |
US8969543B2 (en) | 2003-04-03 | 2015-03-03 | Bioneer Corporation | SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof |
EP1608735A4 (en) | 2003-04-03 | 2008-11-05 | Alnylam Pharmaceuticals | Irna conjugates |
CA2521464C (en) | 2003-04-09 | 2013-02-05 | Alnylam Pharmaceuticals, Inc. | Irna conjugates |
KR20060015505A (en) | 2003-04-13 | 2006-02-17 | 엔존 파마슈티컬즈, 인코포레이티드 | Polymeric oligonucleotide prodrugs |
EP1625138A4 (en) | 2003-04-17 | 2010-06-23 | Alnylam Pharmaceuticals Inc | Protected monomers |
US7851615B2 (en) | 2003-04-17 | 2010-12-14 | Alnylam Pharmaceuticals, Inc. | Lipophilic conjugated iRNA agents |
DK1620544T3 (en) | 2003-04-17 | 2019-01-14 | Alnylam Pharmaceuticals Inc | MODIFIED iRNA AGENTS |
US20100170000A9 (en) | 2004-10-25 | 2010-07-01 | Devgen Nv | Rna constructs |
AU2006275579B2 (en) | 2005-08-01 | 2012-10-04 | Purdue Research Foundation | Multivalent RNA nanoparticles for delivery of active agents to a cell |
US20080214436A1 (en) | 2007-01-26 | 2008-09-04 | City Of Hope | Methods and compositions for the treatment of cancer or other diseases |
US20080287383A1 (en) | 2007-03-02 | 2008-11-20 | Nastech Pharmaceutical Company Inc. | Nucleic acid compounds for inhibiting erbb gene expression and uses thereof |
WO2008109105A2 (en) | 2007-03-06 | 2008-09-12 | Flagship Ventures | Methods and compositions for improved therapeutic effects with sirna |
WO2009126933A2 (en) | 2008-04-11 | 2009-10-15 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
EP2395085B1 (en) * | 2009-02-04 | 2015-06-10 | Sungkyunkwan University Foundation for Corporate Collaboration | Small interference rna complex with increased intracellular transmission capacity |
KR101141544B1 (en) | 2009-03-13 | 2012-05-03 | 한국과학기술원 | Multi-conjugate of siRNA and preparing method thereof |
KR101678876B1 (en) | 2010-01-15 | 2016-11-23 | 한국과학기술원 | Multi-conjugate of siRNA targeting multiple genes and preparing method thereof |
AU2011223820B2 (en) * | 2010-03-01 | 2016-01-14 | The Children's Hospital Of Philadelphia | Nucleic acids for targeting multiple regions of the HCV genome |
KR101340290B1 (en) | 2011-09-14 | 2013-12-11 | 한국과학기술원 | NANOSTRUCTURED siRNA HYDROGELS FOR GENE SILENCING AND PREPARING METHOD THEREOF |
WO2013040429A1 (en) | 2011-09-14 | 2013-03-21 | Rana Therapeutics Inc. | Multimeric oligonucleotide compounds |
EP2895200B1 (en) | 2012-09-14 | 2019-11-06 | Translate Bio MA, Inc. | Multimeric oligonucleotide compounds |
CN108026527B (en) * | 2015-06-15 | 2022-05-10 | Mpeg La有限责任公司 | Defined multiconjugated oligonucleotides |
-
2018
- 2018-02-06 CN CN201880010283.4A patent/CN110248665A/en active Pending
- 2018-02-06 IL IL267806A patent/IL267806B2/en unknown
- 2018-02-06 KR KR1020197023090A patent/KR102623311B1/en active IP Right Grant
- 2018-02-06 CA CA3051480A patent/CA3051480A1/en active Pending
- 2018-02-06 JP JP2019542485A patent/JP7183167B2/en active Active
- 2018-02-06 SG SG11201906728TA patent/SG11201906728TA/en unknown
- 2018-02-06 WO PCT/US2018/017062 patent/WO2018145086A1/en active Application Filing
- 2018-02-06 EP EP18747398.8A patent/EP3576752A4/en active Pending
- 2018-02-06 MX MX2019009347A patent/MX2019009347A/en unknown
- 2018-02-06 KR KR1020247000303A patent/KR20240010750A/en not_active Application Discontinuation
- 2018-02-06 US US15/889,975 patent/US11078484B2/en active Active
- 2018-02-06 IL IL307726A patent/IL307726A/en unknown
- 2018-02-06 AU AU2018215684A patent/AU2018215684B2/en active Active
-
2021
- 2021-07-01 US US17/305,225 patent/US20210380979A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
IL267806B2 (en) | 2024-03-01 |
KR102623311B1 (en) | 2024-01-10 |
AU2018215684B2 (en) | 2024-03-07 |
IL267806B1 (en) | 2023-11-01 |
WO2018145086A1 (en) | 2018-08-09 |
KR20240010750A (en) | 2024-01-24 |
IL307726A (en) | 2023-12-01 |
JP7183167B2 (en) | 2022-12-05 |
IL267806A (en) | 2019-09-26 |
CA3051480A1 (en) | 2018-08-09 |
MX2019009347A (en) | 2019-10-07 |
JP2020518552A (en) | 2020-06-25 |
CN110248665A (en) | 2019-09-17 |
EP3576752A4 (en) | 2020-12-16 |
US20180223284A1 (en) | 2018-08-09 |
EP3576752A1 (en) | 2019-12-11 |
US20210380979A1 (en) | 2021-12-09 |
US11078484B2 (en) | 2021-08-03 |
AU2018215684A1 (en) | 2019-08-01 |
KR20190115445A (en) | 2019-10-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201906728TA (en) | Multimeric oligonucleotides having decreased kidney clearance | |
SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
SG11201909022PA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201908540PA (en) | Stable antibody formulation | |
SG11201906264YA (en) | Improved serum albumin binders | |
SG11201906341XA (en) | Improved serum albumin binders | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201810757YA (en) | Non-human animals expressing exogenous terminal deoxynucleotidyltransferase | |
SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201906961UA (en) | Polypeptide variants and uses thereof | |
SG11201407981RA (en) | Compositions comprising an anti-pdgf aptamer and a vegf antagonist | |
SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
SG11201807677YA (en) | Antibodies to cd40 with enhanced agonist activity | |
SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
SG11201901673SA (en) | Imidazole derivatives and their use in the treatment of autoimmune or inflammatory diseases or cancers | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201809903WA (en) | Method for purification and activation of botulinum neurotoxin | |
SG11201906509WA (en) | Lipocalin muteins with binding affinity for lag-3 | |
SG11201902567WA (en) | Expec glycoconjugate vaccine formulations |